Evidence indicates that lung cancer development is a complex process that involves interactions between tumor cells, stromal fibroblasts, and immune cells. Tumor-infiltrating immune cells play a significant role in the promotion or inhibition of tumor growth. As an integral component of the tumor microenvironment, tumor-infiltrating B lymphocytes (TIBs) exist in all stages of cancer and play important roles in shaping tumor development. Here, we review recent clinical and preclinical studies that outline the role of TIBs in lung cancer development, assess their prognostic significance, and explore the potential benefit of B cell-based immunotherapy for lung cancer treatment.
INTRODUCTION
Lung cancer is a heterogeneous malignant disease that is the leading cause of cancer-related deaths worldwide. 1 The growth, invasion and metastasis of lung cancer is a complex and dynamic process that involves both intrinsic genetic abnormalities of the tumor tissue and its interactions with immune cells within the local microenvironment. 2 Approximately two-thirds of lung tumorinfiltrating immune cells are composed of T and B cells, with the remaining cells being composed of tumor-associated macrophages (TAMs) and a small number of infiltrating dendritic cells and natural killer (NK) cells. 3 These tumor-infiltrating lymphocytes (TILs) are involved in the anti-tumor response within the lung tumor niche. 4 The multifaceted effects of lung cancer-associated T cells have been intensely studied. It has been noted that CD4 + Th1 cells, activated CD8
+ T cells, and γδ-T cells are often involved in type I immune responses and associated with favorable prognosis in lung cancer patients, 5, 6 whereas Th2, Th17, and Foxp3 + regulatory T (Treg) cells are often associated with tumor progression and unfavorable prognosis. 7 Further, clinical responses observed from immune checkpoint blockade therapies (inhibiting the immunological targets PD1/PD-L1 or CTLA4) 8 and CAR-T cell therapies 9 have spurred great interest in the field of anti-tumor immunotherapy. These T cell-targeted therapies have yielded promising clinical results; however, not all patients respond to these therapies, indicating the need for other therapeutic approaches. B cells infiltrating lung cancer have their own unique roles in anti-tumor immunity. Recent studies have demonstrated that proliferating B cells can be observed in~35% of lung cancers. 10 Furthermore, tumor-infiltrating B lymphocytes (TIBs) can be observed in all stages of human lung cancer development, 11 and their presence differs between stage and histological subtypes, 12, 13 suggesting a critical role for B cells during lung tumor progression. TIBs participate in both humoral and cellular immunity, but their roles in antitumor immunity remain controversial.
14 Some studies show the capacity of B cells to induce and maintain beneficial antitumor activity, while others have found that B cells may exert protumor functions due to their various immunosuppressive subtypes. Here, we will review the role of TIBs in lung cancers and discuss their potential clinical applications.
THE INFILTRATION, LOCATION, AND MAINTENANCE OF TIBS IN HUMAN LUNG CANCER
The localization of TIBs is highly controlled by the signals or stimuli within the tumor microenvironment. Evidence has shown that B cell infiltration in human lung cancer is significantly higher than that in surrounding tissue or in distant non-tumoral tissue. 15 The presence of high endothelial venule (HEV) may be critical for driving B cell homing and infiltration into the tumor niche via ligand/receptor interactions of PNAd/CD62L, adhesion molecules, and integrins. 16, 17 Importantly, the B cell chemoattractant CXCL13, secreted by tumor cells, follicular dendritic cells, and T follicular helper cells in human lung tumor lesions, was shown to be responsible for the influx of B cells into the tumor. 16, 18, 19 Upon entering the local microenvironment, tumor antigens released from lung cancer cells aid in B cell aggregation and trigger B cellmediated antigen presentation, which facilitate the maintenance of B cell activation and proliferation. 19, 20 Immunohistochemistry (IHC) and flow cytometric analysis show that all major subsets of B cells can be found within TIB populations (Table 1) . 21 TIBs, including CD20 + B cells and CD138 + plasma cells, primarily localize to lymphoid aggregates within the lung tumor stroma, the typical model being termed a tertiary lymphoid structure (TLS). 10, 22 TLSs exhibit features of secondary lymphoid organs with an ongoing immune reaction and exacerbate the local immune responses in chronic inflammatory settings, including tumors. 23 It has been verified that TLSs form an efficient and beneficial immune response in most solid tumors. 24 Germain et al. described this structure in detail within lung cancer and showed compartmentalized B cell-rich (or follicular area) and T cell-rich zones. B cell-rich areas can be further divided into germinal center (GC) cores and mantle regions. 21 Within the GC, TIBs have an increased GC (Bcl6 21, 22 and B cells proliferate and differentiate into plasma cells. TLS-derived GC-B cells of non-small cell lung cancer (NSCLC) patients expressed activation-induced cytidine deaminase (AID), the enzyme critical for immunoglobulin somatic hypermutation (SHM) and class-switch recombination (CSR). 
CD38
++ /CD138 + ), primarily long-lived plasma cells, accumulate in the follicular periphery, tumor stroma and fibrotic areas, which is sustained by proliferation-inducing ligand + (PRIL + ) myeloid cells in the lung cancer stroma. 13, 26 These observations suggest that B cells can exist in a continuum of naive cells to differentiated plasma cells within the tumor microenvironment.
Importantly, TIBs maintain the structure and function of TLS within the lung tumor microenvironment by secreting cytokines and chemokines. Early studies using murine models have identified CXCL13 and lymphotoxin (LT) 27, 28 as two critical factors in the formation, development, and maturation of isolated lymphoid follicles of the gut. 23 Similarly, in human inflamed lungs, such as in chronic obstructive pulmonary disease and lung cancer, B cells produce CXCL13 and LT via toll-like receptor 4 signaling, which positively correlates with the formation and high density of TLS. 29, 30 Analysis of the factors secreted by TIB, as shown in Fig. 1 , provides evidence of ongoing B cell proliferation and induction of antitumor immunity of TLS. Of note, murine models have shown the presence of TLS and follicular B cells in melanoma and/or pulmonary metastasis via LT. 31, 32 However, some premalignant and malignant tissues in mice are poorly infiltrated by B cells. 33, 34 The difference in status of TLS-containing follicular B cells in particular experimental settings to some extent may explain why murine models do not recapitulate all clinical-pathological features of human disease.
PROTECTIVE EFFECT OF TIBS FOR ANTI-TUMOR IMMUNITY IN LUNG CANCER
The development of humoral immunity is the primary function of B cells. Within the lung, tumor-associated B cells can differentiate into plasma cells and produce tumor-specific antibodies that recognize and react against tumor-associated antigens, such as LAGE-1, TP53, and NY-ESO-1. 21 Lung cancer patients with a higher proportion of tumor-associated antigen reactive immunoglobulin tend to have a higher density of follicular B cells. 21 Moreover, both follicular B cells and tumor-infiltrating plasma cells are correlated with a better long-term survival of lung cancer patients, indicating the protective role of plasma cells and antibodies in antitumor immunity (see section below for detail). 21, 35 In accordance with this evidence, increased tumor B cell-derived IgG in the sera is associated with a significantly higher number of tumor regressors in murine xenograft models of human lung squamous cell carcinoma (SCC) tissue. 36 Furthermore, immunoglobulins secreted by lung tumor-stimulated B cells can mediate tumor lysis by antibody-dependent cellular cytotoxicity (ADCC) or complementdependent cytotoxicity (CDC). 37, 38 In addition to the production of antibodies, B cells also promote tumoral T cell responses, such as regulation of T cell activation, expansion, and memory formation. Studies have demonstrated that increased levels of CD8 + and CD4 + TILs co-localizing with high CD20
+ B cell infiltration are related to long-term survival in NSCLC. 6, 39 Further, studies by Eerola et al. showed a significant association between B cells and CD8
+ TILs in large cell lung carcinoma (LCC). 40 These data suggest the beneficial effect of TIBs on T cell-mediated antitumor immunity, possibly through antigen presentation by TIBs. Experimental data from studies in human/ murine lung tumor models provide support for B cell interaction with T cells. Tumor-stimulated B cells can rapidly increase the expression of HLA class II and the costimulatory molecules CD40, CD80, and CD86. [41] [42] [43] Tumor antigen can be presented by TIBs to tumor-infiltrating CD4 + T cells, which leads to CD4 + T cell differentiation and clonal expansion. 41 Specifically, B cells with the CD69 + HLA-DR + CD27 + CD21 + phenotype in NSCLC patients correlated with an effector T cell response (IFN-γ + CD4 + TILs). 41 A similar ability of lung TIB cells to induce T cell secretion of IFN-γ has been reported in murine models of lung metastatic tumors. 42 Consistently, evidence suggests that an increase in CD4 + and CD8
+ TCR repertoire clonality is closely associated with a high density of follicular B cells within the lung tumor niche. 44 Although likely not a major mechanism, evidence exists that the activated B cells can directly lyse tumor cells. TIBs have been shown to have cytotoxicity towards hepatoma cells via secretion of granzyme B and TRAIL, 45 and human B cells stimulated with IFN-α or a toll-like receptor 9 agonist produce functional TRAIL that is cytotoxic towards melanoma cell lines. 46 However, IL-21-induced granzyme B-expressing B cells are detrimental, as they can suppress antitumor T cell responses. 47 Figure 1 summarizes the current understanding of the dynamic conversion processes and immunomodulatory effects of B cells in lung cancer. A better understanding of the functional properties of TIBs in lung cancer will help develop improved immunotherapies against lung cancer. Naive B CD20
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As part of a continuum of B cell phenotypes, Bregs likely acquire their regulatory phenotype within the lung tumor microenvironment. 52 The polarization of B cells to high IL-10-secreting cells is associated with high expression of inflammatory signals either derived from the tumor directly or indirectly by other microenvironment constituents. [53] [54] [55] [56] In one model, LPS-stimulated lung cancer cells alone could polarize B cells to a Breg phenotype. Polarization was attributed to high secretion of RANTES, MIP-α, TNF-α, and TGF-β; thus, at least some differentiation factors could be directly attributed to epithelial tumor cells. 57 Other signals, such as IL-21 and TGF-β, may be derived from other tumorinfiltrating or resident cells, as IL-21 is not known to be epithelial derived. 58 Importantly, IL-10+ Bregs have been associated with tumor progression in experimental models 33, [48] [49] [50] [51] [59] [60] [61] [62] [63] with some evidence to suggest their inhibitory role in human lung cancer ( Fig. 1) . 52, 57 In murine preclinical models, data suggest that B cells may hamper chemotherapy. In an autochthonous transgenic murine model for prostate cancer, the presence of IgA/IL-10/PD-L1 + plasma cells reduced tumor response to oxaliplatin, which could be restored in B cell-deficient mice. 59 Similarly, using a K14-HPV-induced squamous carcinoma model, Coussen's group has shown that cancer development was dependent on B cellmediated FcγR engagement and that depletion of B cells (by anti-CD20) was complementary to platinum-based and Taxol-based chemotherapy for carcinoma. 33, 60 Additionally, in murine models of lung metastasis, tumor angiogenesis is primarily dependent on B cell-mediated induction of VEGF, which requires Stat3 signaling in B cells. 61 Lung metastasis was shown to require the participation of active Stat3-expressing Bregs that can promote TGF-β-mediated conversion of CD4 + TILs to Tregs, inhibit tumoricidal activity of NK cells, or directly activate MDSC. 62, 63 Data on the role of Bregs in human studies are more limited, with some indication of the presence of these cells in human lung cancer. For example, a high frequency of CD19 +
IL-10
+ Bregs have been found within lung cancer patients, 57 and CD24 hi IL-10 + B cells that display a plasma cell-like gene signature are elevated in lung tumors but not found in normal lung tissue. 52 Further, an increase in IL-10-producing Bregs is associated with an increased frequency of peripheral Tregs and MDSC in the advanced clinical stage of lung cancer, 64 suggesting that together with murine models, IL-10 + Bregs may be detrimental to human disease. Breg activity has been found within Stat-regulated tumors, which together with NF-κB co-regulate numerous oncogenic and inflammatory genes. Stat3-driven Bregs are negatively associated with survival in ovarian cancer 66 and have been identified in the tumor-draining lymph nodes (TDLN) of lung cancer patients. 67 These Bregs characterized by a CD19 + CD5 + phenotype driven by Stat3 activation and IL-6-induced CD5 over-expression are thought to promote tumor progression by inducing tumor angiogenesis and immunosuppression through production of IL-10. 67 Together, the published data suggest that the presence of human Breg phenotypes maybe associated with inflammation; however, it is unclear whether they are bystanders or actively promote cancer.
Thus, the capacity of Bregs for attenuation of immune responses has been clearly demonstrated in multiple experimental models of cancer. 53 However, much remains to be understood regarding the biology of Bregs in human lung cancer. For example, the identification of a unique Breg signature, the mechanisms that control Breg differentiation, and a complete understanding of the interactions between Bregs and the tumor microenvironment will provide a clearer role of this population in lung cancer progression. Role 
PREDICTIVE VALUE OF TIB FOR THE PROGNOSIS OF HUMAN LUNG CANCER
The presence of B cells in human lung tumors has been correlated with patient prognosis, as summarized in Table 2 . The number of intratumoral GCs and/or B cells was found to be inversely correlated with lung cancer stage. 10 Generally, when identified by CD20 for total B cells, the presence of B cells infiltrating NSCLC tumor is overwhelmingly favorable for long-term overall survival (OS), recurrence-free survival (RFS), or disease-specific survival (DSS) of NSCLC, 6, 21, 39, 40, [68] [69] [70] with a few exceptions that did not identify any significant associations 6, 71, 72 or negative associations with the disease. 13 No significant association between TIBs and prognosis was observed for small cell lung cancer (SCLC). 73 Among studies that show favorable TIB presence, no difference in prognostic outcome was observed between patients with earlystage or late-stage tumors, 21 suggesting that the presence of B cells can affect outcome at all stages of disease. Further, the presence of common driver mutations such as EGFR, KRAS, and TP53 in lung adenocarcinoma (ADC) was found to have no effect on B cell infiltration or their prognostic values. 52, 74 Although most studies indicate a favorable outcome of TIBs in NSCLC, prognostic impact differs when analyzed with clinical correlates such as histological subtype and location. In studies with mixed tumor subtypes, most studies indicate that the prognostic relevance was restricted to ADC, 39, 68 with one study showing relevance in only SCC 69 or LCC. 40 Further, when the location of TIBs was analyzed for all NSCLC subtypes, most studies indicated that a stromal 6, 21, 70 or marginal 68 infiltrate, rather than an intraepithelial infiltrate, was associated with favorable prognosis. Interestingly, a favorable outcome for intraepithelial TIBs was only observed in samples that show SCC or LCC as the prognostic subtype, 40, 69 suggesting that mechanisms of B cell regulation of tumors may differ among lung cancer subtypes. The prognostic difference observed among studies may be due to the interpatient heterogeneity within the study cohorts or biological differences in TIB infiltration among the tumor subtypes. For example, a greater abundance of CD20 + B cell infiltration has been observed in ADC than in SCC or LCC. 6, 40 Interestingly, SCLC has a greater abundance of infiltrating T cells and TAMs but few TIBs, which may account for the low prognostic value of TIBs in SCLC. 73 In addition to the beneficial prognostic value of total B cell infiltration, the role of tumor-infiltrating plasma cells, identified as CD138 + cells, has been explored. Unlike the overwhelming evidence for the prognostic benefit of total B cell infiltration, plasma cell analysis has yielded more conflicting results, with data correlating to favorable prognosis, 35, 75, 76 no prognostic value, 71, 77 or adverse prognosis. 13 Analysis of clinical correlates such as NSCLC subtype or location could not explain the differences observed among different studies, as both ADC or SCC subtypes with stromal infiltrating plasma cells were shown to have favorable outcomes in some reports 35, 75, 76 but not by others when similar subtypes and locations were analyzed. 71, 77 One ADC study deviates from the others that indicate a favorable role of B cells in prognosis. Kurebayashi et al. show that when analyzed in the presence of other immune cells, high infiltrates of plasma cells may be indicative of poor outcomes, suggesting that the prognostic value of B cells may change in the context of other cells. 13 Notably, four studies have performed additional analysis of immunoglobulin isotypes. 13, 35, 75, 76 IgG 4 -producing plasma cells were determined to be a positive prognostic factor in SCC. 76 In contrast, subset analysis of an ADC cohort demonstrated that the presence of IgA + rather than IgG 4 + plasma cells trended towards an adverse prognosis; however, statistical significance was not reached. 13 This observation is consistent with the known immunosuppressive effects of IgA + plasma cells on chemotherapy models, 59 as well as with IgG-positive cells (IGκC + cells) as good predictors in ADC. 35, 75 Overall, given that class-switching and the role of immunoglobulins is considerably affected by different cytokine/chemokine milieus, such as Th2-biased conditions to support regulatory IgG 4 or IgA production by plasma cells in the human melanoma microenvironment, 78 differences in the presence or effects of each immunoglobulin may exist between each histological subtype of lung cancer. 79 Further studies of isotypespecific plasma cells in different subtypes of lung cancer are required to determine this relationship.
Molecular characterization of NSCLC has revolutionized our understanding of lung cancer. 80, 81 Coupled with immune subset deconvolution algorithms, 82 a more complete understanding of the role of immune infiltrates can be determined with the genomic data alone. Among genomic studies, several B cellassociated gene signatures have been found to correlate with lung cancer prognosis. Gene signatures consisting primarily of humoral immunity-related genes have been shown to predict improved OS in lung ADC. 70, 75, 83 In addition, a 24-gene signature, dominated by B cell lineage-related genes, was identified to be predictive of clinical outcome of early-stage SCC. 84 Finally, in a pan-cancer analysis of leukocyte gene signatures, analysis of B cell subgroup signatures, including naive, memory B cells and plasma cells, showed that all three B cell signatures have a strong trend of favorable outcomes of lung ADC, whereas memory B cell and plasma cell signatures significantly denoted adverse outcomes of SCC and LCC, respectively. 82 Overall, similar to the histological identification of B cells, the genomic presence of B cells, including pan-B cells and B cell subtypes, generally shows different prognosis outcomes among subtypes.
Beyond standard histological classification of tumor subtypes, molecular characterization allows for additional stratification of NSCLC ADC or SCC. Differences among molecular subtypes and B cell signatures have been observed. 74 In analyses considering the molecular subtypes of ADC or SCC, immune infiltrates have been associated with survival in NSCLC. For example, B cell signature is higher in the "squamoid" and "bronchioid" molecular subtypes of lung ADC, while the presence of TIBs is associated with relatively better prognosis of only the squamoid subtype. 74 The analyses of the representation of the B cell subgroup and molecular subtype of lung cancer can optimize and improve the assessment of the prognostic impact of TIBs in lung cancer.
The lack of a universally accepted method for evaluating antitumor versus protumor B cells makes it difficult to evaluate the role of TIBs in cancer. In general, the presence of CD20 41, 67 but as Bregs share common markers with anti-tumor B cells, their contribution will be difficult to discern. Future research efforts should focus on investigating biomarkers that might differentiate anti-tumor B cells from Bregs and developing more robust analytical platforms that combine multiple techniques such as multi-chromatic flow cytometry, IHC, and/or gene sequencing studies together with data from clinical outcomes. 
TIB-BASED IMMUNOTHERAPY IN LUNG CANCER
Despite advances in surgery, chemotherapy and radiation therapy, lung cancer continues to have a low survival rate. 1, 85 Given the prognostic benefit of B cells, development of B cell-based immunotherapeutic strategies may be attractive.
14 Targeted approaches for enhancing conventional B cells through stimulation with B cell ligands can effectively inhibit tumor growth and lung metastasis, as exhibited in several murine models (Table 3) . After activation in vitro, CpG-activated B cells and TDLN-B cells have been shown to display immunoenhancing properties after adoptive transfer. [86] [87] [88] Therapeutic efficacies of these B cells were associated with increased antitumor responses by antibodyspecific recognition, lysis of tumor cells, reduction of the immunosuppressive environment, and/or tumoricidal-cell response via the Fas/FasL pathway. Additionally, B cells that are activated directly in vivo show effective tumor inhibition. For example, CXCR5-expressing B cells, stimulated by CXCL13-coupled CpG-ODN, can trigger the cytolytic effect of CD8 + TILs, leading to abrogation of lung metastases in 4T1.2 tumor-bearing mice. 89 Further, natural compounds, such as Reishi polysaccharide fraction, can suppress tumor growth using CD138 + B cells via activating IgM-mediated cytotoxicity, as exhibited in a Lewis lung tumor mouse model. 90 Alternatively, given the role of Bregs, strategies have been devised in experimental models that target depletion/reversal of pathological B cells (Table 3) . Early tumor pulmonary metastasis models showed significant improvement in survival by depleting B cells with anti-CD20 antibodies, including rituximab. 91, 92 Unfortunately, there was no marked clinical benefit in some solid tumors, such as renal cell, colorectal carcinoma, and melanoma. 14 
Because CD20
+ B cells have been shown to correlate with good outcomes in NSCLC, 21 depletion of CD20 + B cells could be detrimental to lung cancer treatment. 93 Indeed, it was subsequently found that anti-CD20 antibodies may deplete antitumor B cells and possibly enrich for CD20 low Bregs, thus exacerbating tumor growth. 89 Recently, several chemical modulators have been observed to selectively inhibit Bregs. For example, CpG-ODN significantly reduced CD20 low Bregs while activating antitumor B cells, leading to inhibition of lung metastasis in 4T1 tumor-bearing mice. Resveratrol efficiently prevented the generation and function of Bregs in a similar animal model. 94 Other mediators, such as total glucosides of paeony and Lipoxin A4, also exerted an antitumor effect by inhibiting Bregs. 95, 96 These molecules attenuated the expansion of Bregs by inactivating Stat3 and/or ERK, leading to a reduction in IL-10 or TGF-β, which further decreases Breg-induced Treg generation. 94, 96 In addition, the inactivation of the 5-lipoxygenase/leukotriene/PPARα pathways in Bregs, for example, using MK886 is sufficient to abrogate cancer escape and metastasis through the loss of Tregs and the release of effector CD8
+ T cells in lung metastasis. 97 Overall, B cell-based therapies, except rituximab, are still in preclinical studies, which are classified into three major strategies, including adoptive transfer of stimulated effector B cells, antitumor B cell activation and Breg inhibition in vivo. These B cell-based strategies primarily promote cytotoxic T cells and/or inhibit downstream immunosuppressive pathways, resulting in antitumor immune responses. Future studies will be needed to develop approaches to effectively induce B cells to amplify antitumor responses by other immune cells.
CONCLUSION AND PERSPECTIVE Our current understanding indicates that tumor-infiltrating B cells are important regulators of lung cancer progression. Driven by signals within the tumor microenvironment, B cells infiltrate, proliferate, and develop in tumors. TIB exert anti-tumor immunity through secretion of tumor-specific antibodies, promoting T cell responses, and maintaining the structure and function of TLS, all of which are associated with beneficial outcomes for lung cancer. However, as multifaceted effectors, B cells can develop into IL-10-secreting immunosuppressive phenotypes, leading to tumor progression. Novel immunotherapeutic strategies targeting B cells will have to both promote antitumor B cells and inhibit Breg phenotypes. Further exploration of B cell function within the lung tumor microenvironment will allow for improved therapeutic strategies to target this important subset of immune cells.
